Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
endostatin + pembrolizumab + sintilimab + toripalimab
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of endostatin (an angiogenesis inhibitor) and three PD-1 inhibitors (pembrolizumab, sintilimab, and toripalimab). Endostatin blocks abnormal angiogenesis in tumor cells, while PD-1 inhibitors prevent cancer cells from suppressing the immune system by blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), allowing T cells to recognize and attack cancer cells.
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on endostatin + pembrolizumab + sintilimab + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on endostatin + pembrolizumab + sintilimab + toripalimab.